Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H1299 Lysate Vaccine + Entinostat + Nivolumab in Esophageal Cancer
NCT05898828Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Aug 2024
- Primary completion
- Aug 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of H1299 cell lysate vaccine in esophageal cancer, sponsored by National Cancer Institute. Planned start Aug 2024; status: withdrawn.
02
Drugs
H1299 cell lysate vaccine
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT05898828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05898828.